SCHEMBL23356015

SCHEMBL23356015

CS(=O)(=O)Nc1n[nH]c2nc(Nc3cccc4c3CCC4)c(F)cc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GSK3A P49840 1/20 0.40
▸ GSK3B P49841 1/20 0.40
▸ ZAP70 P43403 1/20 0.39
▸ NISCH Q9Y2I1 1/20 0.39
▸ EGFR P00533 1/20 0.37
▸ ALDH1A1 P00352 2/20 0.36
▸ ULK1 O75385 1/20 0.36
▸ LMNA P02545 3/20 0.36
▸ NPSR1 Q6W5P4 1/20 0.36
▸ CYP2D6 P10635 1/20 0.35
▸ CYP2C19 P33261 1/20 0.35
▸ KDM4E B2RXH2 1/20 0.34
▸ GAA P10253 1/20 0.34
▸ HTT P42858 1/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ KCNK2 O95069 1/20 0.34
▸ KCNK10 P57789 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ KCNK18 Q7Z418 1/20 0.34
▸ TDP1 Q9NUW8 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30791254 1.00 GSK3A (0.40) GSK3AGSK3BZAP70NISCHEGFR
SCHEMBL23356090 0.87 NISCH (0.42) ZAP70NISCHEGFRALDH1A1ULK1
SCHEMBL30791245 0.87 NISCH (0.42) ZAP70NISCHEGFRALDH1A1ULK1
SCHEMBL30791290 0.84 ALDH1A1 (0.42) ZAP70NISCHEGFRALDH1A1ULK1
SCHEMBL23356047 0.84 ALDH1A1 (0.42) ZAP70NISCHEGFRALDH1A1ULK1
SCHEMBL23356095 0.83 NISCH (0.43) ZAP70NISCHEGFRALDH1A1ULK1
SCHEMBL30791217 0.83 NISCH (0.43) ZAP70NISCHEGFRALDH1A1ULK1
SCHEMBL23356021 0.83 NISCH (0.42) ZAP70NISCHEGFRALDH1A1ULK1
SCHEMBL30791210 0.83 NISCH (0.42) ZAP70NISCHEGFRALDH1A1ULK1
SCHEMBL23356028 0.82 EGFR (0.46) ZAP70NISCHEGFRULK1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12583852-B2 Heterocycle derivative JW PHARMACEUTICAL CORPORATION (KR) 2026-03-24 — — US disclosed
CN-112313232-B Novel heterocyclic derivatives JW中外制药公司 2024-03-08 — — CN disclosed
US-20220259199-A1 NOVEL HETEROCYCLE DERIVATIVE JW PHARMACEUTICAL CORPORATION (KR) 2022-08-18 — — US disclosed
EP-3822270-A1 NOVEL HETEROCYCLE DERIVATIVE JW Pharmaceutical Corporation (KR) 2021-05-19 — — EP disclosed
CN-112313232-A Novel heterocyclic derivatives JW中外制药公司 2021-02-02 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12583852-B2 Heterocycle derivative AR, SRD5A1, NR5A1 GSK3A 439/4885GSK3B 361/4885ZAP70 2340/4885
US-20220259199-A1 NOVEL HETEROCYCLE DERIVATIVE AR, BRDT, NR5A1 GSK3A 1526/4885GSK3B 1258/4885ZAP70 1807/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback